SKLB-C05
SKLB-C05 is a novel selective, orally active TOPK inhibitor, with an IC50 of 0.5 nM. SKLB-C05 selectively inhibit TOPK kinase. SKLB-C05 induces Apoptosis, downregulates c-Myc, γ-H2AX, activates p53, blocks FAK/Src medicated migration-related signaling. SKLB-C05 disturbs cell mitosis. SKLB-C05 shows anticancer activity only against TOPK-positive colorectal cancer[1].
Product Specifications
CAS Number
2300981-68-2
UNSPSC
12352005
Target
Apoptosis; c-Myc; FAK; MDM-2/p53; Mitosis; Src; TOPK
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C1NC2=C(C)C=C(O)C(C3=CC=C(C=C3)[C@H](CN)C)=C2C4=C1C=CC=C4.Cl
Molecular Formula
C23H23ClN2O2
Molecular Weight
394.89
References & Citations
[1]Gao T, et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Cancer Lett. 2019 Mar 31;445:11-23.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD63 (MX-49.129.5), CF594 conjugate, 0.1mg/mL
TYRP1 (Tyrosinase Related Protein 1) (TA99), CF405S conjugate, 0.1mg/mL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF640R conjugate, 0.1mg/mL
